Celularity Secures $2 Million in Private Placement

The latest announcement is out from Celularity ( (CELU) ).

On October 24, 2025, Celularity Inc. entered into a Securities Purchase Agreement with an institutional investor to issue and sell Series A Convertible Preferred Stock and accompanying warrants in a private placement transaction. The initial tranche closed on the same day, providing the company with approximately $2 million in gross proceeds. The funds are intended for working capital and general corporate purposes, potentially impacting the company’s financial flexibility and market operations. The agreement includes provisions for conversion, voting rights, and dividend entitlements, with implications for shareholder equity and market positioning.

The most recent analyst rating on (CELU) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.

Spark’s Take on CELU Stock

According to Spark, TipRanks’ AI Analyst, CELU is a Underperform.

Celularity’s overall stock score is primarily impacted by its financial performance, which shows significant revenue growth but ongoing unprofitability and financial risks. Technical analysis indicates bearish momentum, and valuation metrics are poor due to negative earnings. The lack of earnings call data and corporate events further limits positive influences on the score.

To see Spark’s full report on CELU stock, click here.

More about Celularity

Celularity Inc. operates in the biotechnology industry, focusing on developing innovative cellular therapies. The company primarily deals with products derived from placental-derived cells, targeting cancer, infectious diseases, and degenerative diseases.

Average Trading Volume: 145,375

Technical Sentiment Signal: Strong Sell

Current Market Cap: $55.25M

See more data about CELU stock on TipRanks’ Stock Analysis page.